HOMOLOGY MEDICINES INC (FIXX)
US4380831077 - Common Stock
Homology Medicines Declares Distribution to Common Stockholders
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common...
FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023
FIXX stock results show that Homology Medicines beat analyst estimates for earnings per share the fourth quarter of 2023.
FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Homology Medicines (NASDAQ:FIXX) just reported results for the fourth quarter o...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AGE, GRPH, FIXX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Homology Medicines gets non-compliance notice from Nasdaq (NASDAQ:FIXX)
Homology Medicines receives notification from Nasdaq regarding minimum bid price deficiency.
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03,...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MIRO, SRC, PATI, FIXX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to Shareholders
Homology Medicines stock slumps after merger deal
Homology Medicines (FIXX) shares fall 47% as gene therapy firm is set to merge with Q32 Bio, a clinical-stage biotech focused on autoimmune conditions. Read more here.
Q32 Bio and Homology Medicines Announce Merger Agreement
--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio’s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders--
Q32 Bio and Homology Medicines Announce Merger Agreement
--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase...
Homology Medicines Reports Third Quarter 2023 Financial Results
- Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 - BEDFORD, Mass., Nov. 14, 2023 ...
Homology Medicines stock spikes on strategic review
Homology Medicines (FIXX) added ~23% pre-market Friday after announcing plans to evaluate strategic alternatives, including potential sale of assets. Read more here.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting off the day with a breakdown of all the biggest pre-market stock movers traders need to know about on Friday!
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
Participant 1 Achieved Clinically Meaningful Reduction in Plasma Phe of Up to 99% Change from Baseline and Below the U.S. PKU Treatment Guideline Threshold...
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting
- New Preclinical Data Demonstrated Ability to Re-Dose with AAVHSCs Across Viral Clades, Potentially Expanding Possibilities of Genetic Medicine Programs...
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 - - First Presentations of Preclinical Data with GTx-mAb...
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting
- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration...
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
BEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced two presentations...
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year with First Participant Dosed and Others in Screening - - Initial...
Homology Medicines gets new chief medical officers (NASDAQ:FIXX)
Genetic medicines company, Homology Medicines (FIXX) announced that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously, Dr
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie...